MindMed stock is surging today following a recent report from a Minnesota-based task force that urged the decriminalization of psychedelic mushrooms. The clinical-stage biotech specialist is focused ...

MindMed is a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of ...

MindMed has announced the dosing of the first patient in its phase 3 Voyage study of MM120 ODT, a pharmaceutically optimised form of lysergide D-tartrate (LSD) for treating Generalised Anxiety ...

2024 Turns Out to Be a Transformational Year for MindMed 2024 was a transformational year for the company when it executed many important milestones, one of which was initiating the 52-week Voyage ...

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel ...

In another inflection point for the psychedelic medicines category, Mind Medicine (MindMed) has claimed breakthrough status from the FDA for its LSD-based candidate MM120 as a treatment for anxiety.

Inc. (NASDAQ:MNMD – Get Free Report) shares were down 8.5% on Friday following insider selling activity. The company traded ...

MindMed Posters are available on MindMed’s Company website. About MindMed MindMed is a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders.

Geode Capital Management LLC boosted its holdings in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Free Report) by 10.8% during ...